STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global Healthcare Conference:Location: New York, New York Format: Fireside chat and 1×1 meetings Webcast: Link Presentation Date and Time: Thursday June 4th at 2:35 PM Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO For more information, please contact:Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.comHans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.comAbout Vicore PharmaVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.comAttachmentsVicore Pharma to Present at the Jefferies Global Healthcare ConferenceSOURCE: Vicore Pharma HoldingView the original press release on ACCESS Newswire
Vicore Pharma to Present at the Jefferies Global Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global Healthcare Conference:Location: New York, New York Format: Fireside chat and 1×1 meetings Webcast: Link Presentation Date and Time: Thursday June 4th at 2:35 PM Participants: Ahmed Mousa, CEO, and Bernt van den Blink, CMO For more information, please contact:Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.comHans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.comAbout Vicore PharmaVicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.comAttachmentsVicore Pharma to Present at the Jefferies Global Healthcare ConferenceSOURCE: Vicore Pharma HoldingView the original press release on ACCESS Newswire
